AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11540403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1858618 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (group I)
Number of subjects: 114
Study 1858618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pumping (IABP) for 25 +/- 8 hours (group II)
Number of subjects: 114
Study 1858618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pumping (IABP) (group II)
Number of subjects: 114
Study 31461183 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap and grafting (flap-graft)
Number of subjects: 45
Study 31461183 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap and no grafting (flap-nograft)
Number of subjects: 45
Study 31461183 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless and no grafting (noflap-nograft)
Number of subjects: 45
Study 31461183 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 45
Study 28292304 — intervention group
Group type: EXPERIMENTAL
Intervention: iCPR tool with academic detailing about strep pharyngitis and pneumonia diagnosis and treatment
Number of subjects: 33
Study 28292304 — intervention group
Group type: COMPARATOR
Intervention: Control group with academic detailing about strep pharyngitis and pneumonia diagnosis and treatment
Number of subjects: 33
Study 28292304 — intervention group
Group type: EXPERIMENTAL
Intervention: iCPR tool
Number of subjects: 33
Study 28292304 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 27004425 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9190 single dose
Number of subjects: 36
Study 27004425 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9190 multiple doses (8 days)
Number of subjects: 36
Study 27004425 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9190 multiple doses (4-6 months follow-up)
Number of subjects: 36
Study 27004425 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric HCV replicons with Y448H and Y448H + Y452H/Y
Number of subjects: 36
Study 25148846 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand and Arm Together (HAT) training (n=20)
Number of subjects: 40
Study 25148846 — intervention group
Group type: COMPARATOR
Intervention: Hand and Arm Separate (HAS) training (n=21)
Number of subjects: 40
Study 25148846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HAT and HAS)
Number of subjects: 40
Study 22735873 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 56
Study 22735873 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 56
Study 20190467 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate monotherapy (n=8)
Number of subjects: 16
Study 20190467 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risedronate and vitamin K(2) therapy (n=8)
Number of subjects: 16
Study 20190467 — intervention group
Group type: COMPARATOR
Intervention: Intravenous steroid pulse therapy (n=6, group C)
Number of subjects: 16
Study 18187011 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational lessons on cancer-related topics (10 sessions)
Number of subjects: 294
Study 15681523 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (2,500 mg/m2/d)
Number of subjects: 462
Study 15681523 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus Bevacizumab (15 mg/kg)
Number of subjects: 462
Study 15681523 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 462
Study 15681523 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus Bevacizumab
Number of subjects: 462
Study 11948045 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV)
Number of subjects: 26
Study 11948045 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen supplementation by Venturi mask
Number of subjects: 26
Study 11877184 — intervention group
Group type: EXPERIMENTAL
Intervention: UBM dark room provocative test
Number of subjects: 52
Study 11877184 — intervention group
Group type: COMPARATOR
Intervention: Traditional dark room provocative test
Number of subjects: 52
Study 11877184 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal persons)
Number of subjects: 52
Study 7622821 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 338
Study 7622821 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 338
Study 7622821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 1663853 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO to achieve a hemoglobin of 95-110 g/L
Number of subjects: 118
Study 1663853 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO to achieve a hemoglobin of 115-130 g/L
Number of subjects: 118
Study 1663853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 1663853 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO therapy (both dosages)
Number of subjects: 118
Study 6972693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed supervised exercise program (intensive exercise in laboratory for 8 weeks, followed by gymnasium exercise for 34 months)
Number of subjects: 651
Study 6972693 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 651
Study 6972693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed supervised exercise program
Number of subjects: 651
Study 6972693 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 651
Study 31694684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine with paravertebral saline
Number of subjects: 153
Study 31694684 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral lidocaine with intravenous saline
Number of subjects: 153
Study 31694684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil with paravertebral saline
Number of subjects: 153
Study 31694684 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine
Number of subjects: 153
Study 28213775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar diathermy scissors
Number of subjects: 60
Study 28213775 — intervention group
Group type: COMPARATOR
Intervention: Harmonic scalpel
Number of subjects: 60
Study 26482768 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage Cryotherapy (SC)
Number of subjects: 0
Study 26482768 — intervention group
Group type: COMPARATOR
Intervention: Androgen Deprivation Therapy (ADT)
Number of subjects: 0
Study 23420911 — intervention group
Group type: EXPERIMENTAL
Intervention: Media diet intervention (substituting high quality prosocial and educational programming for aggression-laden programming)
Number of subjects: 565
Study 23420911 — intervention group
Group type: EXPERIMENTAL
Intervention: Media diet intervention
Number of subjects: 565
Study 21178814 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared light device (device group)
Number of subjects: 123
Study 21178814 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods (standard group)
Number of subjects: 123
Study 21178814 — intervention group
Group type: EXPERIMENTAL
Intervention: Device (qualitative assessment by nurses)
Number of subjects: 123
Study 19833260 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg, followed by 80 mg
Number of subjects: 509
Study 19833260 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg, followed by 80 mg
Number of subjects: 509
Study 19833260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg, followed by 40 mg
Number of subjects: 509
Study 19833260 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1B1*5 genotype
Number of subjects: 509
Study 19833260 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 509
Study 19833260 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-dose effect
Number of subjects: 509
Study 17537739 — intervention group
Group type: EXPERIMENTAL
Intervention: Liaison psychiatric nursing
Number of subjects: 121
Study 17537739 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment by hospital and primary care staff
Number of subjects: 121
Study 15350880 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person verbal interactions
Number of subjects: 29
Study 15350880 — intervention group
Group type: COMPARATOR
Intervention: Remote verbal interactions
Number of subjects: 29
Study 15350880 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal interactions (both conditions)
Number of subjects: 29
Study 15350880 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster-paced verbal task (Experiment 2)
Number of subjects: 29
Study 11519773 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (MP) 200 mg
Number of subjects: 182
Study 11519773 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) 5 mg
Number of subjects: 182
Study 11519773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MP and MPA
Number of subjects: 182
Study 9801119 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (20 microg/day)
Number of subjects: 85
Study 9801119 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/day)
Number of subjects: 85
Study 9801119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 9801119 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study 8010466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early epidural analgesia (bupivacaine)
Number of subjects: 334
Study 8010466 — intervention group
Group type: COMPARATOR
Intervention: Late administration of epidural analgesia (after 5 cm dilation) with prior intravenous nalbuphine (10 mg)
Number of subjects: 334
Study 2686320 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinestrol 1 mg orally twice a day for 3 weeks
Number of subjects: 15
Study 2686320 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 patients with PMDD aged 7 to 9 years)
Number of subjects: 15
Study 843185 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hospitalization
Number of subjects: 74
Study 843185 — intervention group
Group type: COMPARATOR
Intervention: Long-term hospitalization
Number of subjects: 74
Study 31774584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin (20 mg)
Number of subjects: 10
Study 31774584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28855417 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake (0, 5, 10, 15, 25, and 35 mg · kg‐1 · d‐1) with no Cys in the diet
Number of subjects: 5
Study 28855417 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake (0, 2.5, 5, 7.5, 10, and 15 mg · kg‐1 · d‐1) with 21 mg · kg‐1 · d‐1 Cys
Number of subjects: 5
Study 28855417 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (comparison group)
Number of subjects: 5
Study 28855417 — intervention group
Group type: COMPARATOR
Intervention: Comparison of minimum Met requirements between healthy children and children with CRI
Number of subjects: 5
Study 26860015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (1 mg/kg)
Number of subjects: 30
Study 26860015 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.2 mg/kg)
Number of subjects: 30
Study 22802269 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia training
Number of subjects: 71
Study 22802269 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimodal training
Number of subjects: 71
Study 22802269 — intervention group
Group type: COMPARATOR
Intervention: Cold Start condition
Number of subjects: 71
Study 22063375 — intervention group
Group type: EXPERIMENTAL
Intervention: S50-R50 bupivacaine-loaded microsphere (Group B)
Number of subjects: 0
Study 22063375 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% enantiomeric excess bupivacaine-loaded microsphere (Group C)
Number of subjects: 0
Study 22063375 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% enantiomeric excess bupivacaine (Group D)
Number of subjects: 0
Study 22063375 — intervention group
Group type: COMPARATOR
Intervention: Microspheres without local anesthetic (Group A)
Number of subjects: 0
Study 19505304 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAQ orally once daily (ASAQ1)
Number of subjects: 941
Study 19505304 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAQ twice daily (ASAQ2)
Number of subjects: 941
Study 19505304 — intervention group
Group type: COMPARATOR
Intervention: Artemether + lumefantrine (AL) twice daily
Number of subjects: 941
Study 19505304 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAQ1 and ASAQ2
Number of subjects: 941
Study 19505304 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 941
Study 19681252 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital imaging method for tooth color measurement
Number of subjects: 14
Study 15510758 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of ferrous sulfate (200 mg) for 2 months
Number of subjects: 60
Study 15510758 — intervention group
Group type: COMPARATOR
Intervention: Weekly supplementation of ferrous sulfate (200 mg) for 2 months
Number of subjects: 60
Study 11843823 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD + cyclosporin A
Number of subjects: 75
Study 11843823 — intervention group
Group type: COMPARATOR
Intervention: VAD
Number of subjects: 75
Study 9559811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 9
Study 7884022 — intervention group
Group type: EXPERIMENTAL
Intervention: Toloxatone (N = 10)
Number of subjects: 18
Study 7884022 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 8)
Number of subjects: 18
Study 2886110 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate infusion
Number of subjects: 34
Study 2886110 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 34
Study 29806872 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX (380 mg intramuscular injections every fourth week)
Number of subjects: 117
Study 28801415 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrical muscle stimulation (LF‐EMS) at 4 Hz, continuous, 5×60 mins per week for 8 weeks (n=30)
Number of subjects: 60
Study 28801415 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo (skin level stimulation only, n=30)
Number of subjects: 60
Study 26147977 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical simulation intervention group
Number of subjects: 98
Study 26147977 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture control group
Number of subjects: 98
Study 24247300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 μg/kg/min)
Number of subjects: 360
Study 24247300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nesiritide (0.005 μg/kg/min without bolus)
Number of subjects: 360
Study 24247300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 21173349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ross procedure
Number of subjects: 1324
Study 21173349 — intervention group
Group type: COMPARATOR
Intervention: Mechanical valve replacement with optimal self-management anticoagulation therapy
Number of subjects: 1324
Study 18158199 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone oral mini-pulse (OMP) therapy (5 mg orally on 2 consecutive days per week for 3 months)
Number of subjects: 49
Study 18158199 — intervention group
Group type: COMPARATOR
Intervention: Topical triamcinolone acetonide (0.1%) paste (applied thrice daily for 3 months)
Number of subjects: 49
Study 16751936 — intervention group
Group type: EXPERIMENTAL
Intervention: Transeptal approach (TSA)
Number of subjects: 100
Study 16751936 — intervention group
Group type: COMPARATOR
Intervention: Retrograde arterial approach (RAA)
Number of subjects: 100
Study 14598949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis machines disinfected after each session (n = 2)
Number of subjects: 15
Study 14598949 — intervention group
Group type: COMPARATOR
Intervention: Dialysis machines disinfected at the end of the day (n = 2)
Number of subjects: 15
Study 14598949 — intervention group
Group type: EXPERIMENTAL
Intervention: General hygiene precautions reinforcement
Number of subjects: 15
Study 10972608 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% sevoflurane/nitrous oxide 67%/oxygen 33% (sevoflurane group)
Number of subjects: 20
Study 10972608 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate, 0.2 mg/kg (intravenous group)
Number of subjects: 20
Study 8725722 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma tissue factor (TF) concentration
Number of subjects: 498
Study 8725722 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VII activity (FVIIc)
Number of subjects: 498
Study 8725722 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VII antigen (FVIIag)
Number of subjects: 498
Study 8725722 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between TF and FVII
Number of subjects: 498
Study 8725722 — intervention group
Group type: EXPERIMENTAL
Intervention: FVII activity and concentration correlation
Number of subjects: 498
Study 8725722 — intervention group
Group type: EXPERIMENTAL
Intervention: FVII activity with age
Number of subjects: 498
Study 8725722 — intervention group
Group type: EXPERIMENTAL
Intervention: FVII concentration and age correlation
Number of subjects: 498
Study 8725722 — intervention group
Group type: EXPERIMENTAL
Intervention: FVII ratio between FVIIc and FVIIag
Number of subjects: 498
Study 1532760 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy
Number of subjects: 256
Study 1532760 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 256
Study 1532760 — intervention group
Group type: COMPARATOR
Intervention: General practitioner treatment
Number of subjects: 256
Study 1532760 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 256
Study 3986077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 9
Study 3986077 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 9
Study 29730215 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure-specific checklist scored in a binary fashion for evaluation of surgical skill
Number of subjects: 44
Study 29730215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative error rate scores
Number of subjects: 44
Study 29730215 — intervention group
Group type: COMPARATOR
Intervention: Assessment by 5 teams of faculty assessors
Number of subjects: 44
Study 26917497 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCAS‐2 device
Number of subjects: 0
Study 24508922 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 25
Study 24508922 — intervention group
Group type: COMPARATOR
Intervention: De-training
Number of subjects: 25
Study 22219405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) as an adjuvant for air leak control (91 patients)
Number of subjects: 185
Study 22219405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, 94 patients)
Number of subjects: 185
Study 22219405 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 185
Study 22219405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 185
Study 20591399 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab (0.5 mg/0.05 mL)
Number of subjects: 32
Study 20591399 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 32
Study 18978400 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation
Number of subjects: 106
Study 16504620 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration with the 6F Export Aspiration Catheter (Medtronic Corporation)
Number of subjects: 1080
Study 16504620 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty before stent implantation
Number of subjects: 1080
Study 16504620 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 1080
Study 16504620 — intervention group
Group type: COMPARATOR
Intervention: Conventional primary PCI (balloon angioplasty)
Number of subjects: 1080
Study 12665327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening in the first round
Number of subjects: 0
Study 12665327 — intervention group
Group type: COMPARATOR
Intervention: Younger age group (reference)
Number of subjects: 0
Study 11898244 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-activated method
Number of subjects: 61
Study 11898244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pillbox method
Number of subjects: 61
Study 11898244 — intervention group
Group type: COMPARATOR
Intervention: Self-administration of medications (control)
Number of subjects: 61
Study 8814094 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years treatment
Number of subjects: 207
Study 8814094 — intervention group
Group type: COMPARATOR
Intervention: 1 year treatment
Number of subjects: 207
Study 1375802 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 42
Study 1375802 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 42
Study 1375802 — intervention group
Group type: COMPARATOR
Intervention: medical controls
Number of subjects: 42
Study 6703855 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (N = 6)
Number of subjects: 21
Study 6703855 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (N = 7)
Number of subjects: 21
Study 6703855 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (N = 5) after abrupt cessation of therapy
Number of subjects: 21
Study 6703855 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine after abrupt cessation of therapy
Number of subjects: 21
Study 6703855 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 21
Study 31273750 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental agent with adaptive randomization and dose-schedule regimes
Number of subjects: 0
Study 31273750 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood-based approach to handle unobserved toxicity and efficacy outcomes
Number of subjects: 0
Study 31273750 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study to evaluate design performance
Number of subjects: 0